Sopharma AD (BUL:SFA)
Bulgaria · Delayed Price · Currency is BGN · Price in EUR 1.880
+0.010 (0.53%)
At close: May 29, 2026
Sopharma AD Income Statement
Financials in millions BGN. Fiscal year is January - December.
Millions BGN. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 2,659 | 2,610 | 2,129 | 1,875 | 1,663 | 1,603 |
Other Revenue | 33.66 | 22.89 | 18.86 | 13.53 | 8.5 | 8.04 |
| 2,692 | 2,633 | 2,148 | 1,889 | 1,672 | 1,611 | |
Revenue Growth (YoY) | 18.13% | 22.57% | 13.72% | 13.00% | 3.73% | 11.43% |
Cost of Revenue | 2,028 | 2,008 | 1,686 | 1,470 | 1,306 | 1,264 |
Gross Profit | 664.11 | 625.13 | 462.11 | 418.52 | 365.37 | 346.96 |
Selling, General & Admin | 402.83 | 387.75 | 312.53 | 251.19 | 215.55 | 221.99 |
Other Operating Expenses | 22.91 | 23.43 | 11.23 | 18 | 11.76 | 7.3 |
Operating Expenses | 508.24 | 490.27 | 383.22 | 325.22 | 279.51 | 285.48 |
Operating Income | 155.87 | 134.86 | 78.89 | 93.31 | 85.86 | 61.48 |
Interest Expense | -22.18 | -21.5 | -12.94 | -10.98 | -6.02 | -10.79 |
Interest & Investment Income | 3.83 | 3.83 | 2.51 | 3.42 | 3.19 | 4.87 |
Earnings From Equity Investments | 35.66 | 38.33 | 25.83 | 24.47 | 22.64 | 12.09 |
Currency Exchange Gain (Loss) | -1.38 | -1.38 | -5.77 | -1.39 | -0.13 | 2.29 |
Other Non Operating Income (Expenses) | -1.18 | -1.39 | -2.91 | -2.55 | -3.19 | -0.94 |
EBT Excluding Unusual Items | 170.61 | 152.75 | 85.61 | 106.28 | 102.35 | 69 |
Impairment of Goodwill | - | - | - | - | -9.6 | - |
Gain (Loss) on Sale of Investments | - | - | -0.12 | 0.95 | -1.59 | 0.15 |
Gain (Loss) on Sale of Assets | 0.51 | 0.51 | 1.31 | 4.53 | 1.95 | 38.01 |
Asset Writedown | -0.07 | -0.07 | -0.42 | -1.44 | -8.46 | -10.34 |
Legal Settlements | 1 | 1 | 3.98 | - | - | - |
Other Unusual Items | 3.06 | 3.06 | 1.73 | 0.87 | 0.43 | 0.75 |
Pretax Income | 175.11 | 157.24 | 92.08 | 111.2 | 85.08 | 97.57 |
Income Tax Expense | 13.51 | 15.66 | 11.65 | 11.32 | 8.74 | 5.87 |
Earnings From Continuing Operations | 161.6 | 141.58 | 80.43 | 99.87 | 76.33 | 91.7 |
Minority Interest in Earnings | -6.8 | -8.06 | -4.12 | -3.9 | -5.21 | -2.21 |
Net Income | 154.8 | 133.52 | 76.31 | 95.98 | 71.12 | 89.5 |
Net Income to Common | 154.8 | 133.52 | 76.31 | 95.98 | 71.12 | 89.5 |
Net Income Growth | 78.01% | 74.97% | -20.49% | 34.95% | -20.53% | 200.27% |
Shares Outstanding (Basic) | 512 | 343 | 493 | 392 | 364 | 376 |
Shares Outstanding (Diluted) | 512 | 343 | 494 | 415 | 375 | 376 |
Shares Change (YoY) | 6.70% | -30.63% | 19.21% | 10.64% | -0.36% | -0.31% |
EPS (Basic) | 0.30 | 0.39 | 0.15 | 0.24 | 0.20 | 0.24 |
EPS (Diluted) | 0.30 | 0.39 | 0.15 | 0.23 | 0.19 | 0.24 |
EPS Growth | 68.66% | 154.03% | -33.35% | 21.05% | -19.73% | 199.61% |
Free Cash Flow | 37.24 | -26.45 | 42.85 | 20.64 | 90.74 | -96.31 |
Free Cash Flow Per Share | 0.07 | -0.08 | 0.09 | 0.05 | 0.24 | -0.26 |
Dividend Per Share | - | - | 0.052 | 0.330 | 0.200 | - |
Dividend Growth | - | - | -84.33% | 65.00% | - | - |
Gross Margin | 24.67% | 23.75% | 21.51% | 22.16% | 21.86% | 21.53% |
Operating Margin | 5.79% | 5.12% | 3.67% | 4.94% | 5.14% | 3.82% |
Profit Margin | 5.75% | 5.07% | 3.55% | 5.08% | 4.25% | 5.55% |
Free Cash Flow Margin | 1.38% | -1.00% | 1.99% | 1.09% | 5.43% | -5.98% |
EBITDA | 230.05 | 205.65 | 130.72 | 127.86 | 118.97 | 93.85 |
EBITDA Margin | 8.54% | 7.81% | 6.09% | 6.77% | 7.12% | 5.82% |
D&A For EBITDA | 74.18 | 70.78 | 51.83 | 34.56 | 33.11 | 32.37 |
EBIT | 155.87 | 134.86 | 78.89 | 93.31 | 85.86 | 61.48 |
EBIT Margin | 5.79% | 5.12% | 3.67% | 4.94% | 5.14% | 3.82% |
Effective Tax Rate | 7.72% | 9.96% | 12.65% | 10.18% | 10.28% | 6.02% |
Advertising Expenses | - | 1.87 | 1.98 | 2.27 | 22.06 | 27.41 |